Bass Explains The Absurdity Of Horizon Pharma’s Vimovo Patent – ValueWalk Premium
vimovo leading seller

Bass Explains The Absurdity Of Horizon Pharma’s Vimovo Patent

It hasn’t been a full day since we reported Kyle Bass’s last pharma patent challenge against Pozen, and his patent busting hedge fund Coalition for Affordable Drugs has already filed another, this time against Horizon Pharma’s patent on Vimovo.

“Vimovo is a drug that merely combines a generic pain reliever with a generic acid inhibitor—but it costs 66 times more than its component parts based solely on the fact that a single patent examiner . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk
0